Neoadjuvant Chemotherapy for Locally Advanced Thymic Cancer

A Prospective, Phase II Trial of Induction Chemotherapy With Docetaxel/Cisplatin for Masaoka Stage III/IV Thymic Epithelial Tumors

Status

Completed

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01312324

Enrollment

Registered

2011-03-10

Start date

2007-02-28

Completion date

2016-03-31

Last updated

2016-04-20

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Locally Advanced Stage III or IV Thymic Cancer

Keywords

neoadjuvant chemotherapy, thymic cancer

Brief summary

We try to evaluate whether neoadjuvant docetaxel plus cisplatin can increase the complete resection rate in advanced thymic carcinoma.

Interventions

DRUGneoadjuvant docetaxel/cisplatin

3 cycles of docetaxel plus cisplatin docetaxel 75mg/m2 D1 cisplatin 75mg/m2 D1 every 3 weeks

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* histologically confirmed thymic carcinoma * surgically inoperable Masaoka stage III or IV * ECOG 0-2 * at least one measurable disease

Exclusion criteria

* previous myocardiac infarct history within 1 year before the enrollment.

Design outcomes

Primary

Measure	Time frame
Complete resection rate	4-8 weeks later after completion of neoadjuvant chemotherapy

Secondary

Measure	Time frame
the number of patients with adverse events	from enrollment to 6 months after completion of chemotherapy

Countries

South Korea

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026